Gastric Cancer, GastroEsophageal Cancer, Pancreatic Cancer
Conditions
Brief summary
Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.
Detailed description
Patients diagnosed with gastric and gastroesophageal junction or pancreatic cancer after January 2019 at participating sites will be included. Data will be collected from medical records in selected centers that comprise different countries from Latin America. Data collection will begin on the time of site activation. Patients recruited for this study will be identified in the participating sites. Data from clinical, demographic, and socioeconomic variables will be collected. Also, data on treatments performed and outcomes will be abstracted. The patient data sources will be the medical records of the patients. Patients will continue to receive treatment and clinical evaluations for gastric and gastroesophageal junction or pancreatic cancer according to what is determined by their medical team, according to the usual standards of treatment and clinical practice of each center.
Interventions
OTHERObservational study
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Sponsors
Astellas Pharma Inc
Grupo Argentino de Investigación Clínica en Oncología (GAICO)
Latin American Cooperative Oncology Group
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18 years * Histological diagnosis of gastric and gastroesophageal junction cancer (Cohort A) or histological diagnosis of pancreatic cancer (Cohort B); * Advanced disease diagnosis from January 2019: patients can be included prospectively. Advanced disease is defined as metastatic disease or locally advanced disease not amenable to curative therapy; * Availability of adequate medical data for data collection.
Exclusion criteria
* Synchronous invasive tumor or second primary tumor in the last three years (except thyroid tumors or non-melanoma skin); * Nonepithelial histology in Cohort A: Sarcoma, GIST, lymphoma, and tumors of neuroendocrine origin; * Nonepithelial histology in Cohort B: Sarcoma, GIST, lymphoma, pancreatoblastoma, and tumors of neuroendocrine origin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Describe the treatment patterns | During study duration (one year) | Describe the treatment patterns and outcomes of patients with gastric and gastroesophageal junction cancer in Latin America. |
Countries
Argentina, Brazil
Outcome results
None listed